Klingenstein Fields & Co. LLC maintained its stake in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,875 shares of the company’s stock at the end of the second quarter. Klingenstein Fields & Co. LLC’s holdings in Novo Nordisk A/S were worth $424,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Novo Nordisk A/S by 64,406.4% in the first quarter. State Street Corp now owns 5,593,351 shares of the company’s stock valued at $191,740,000 after buying an additional 5,584,680 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Novo Nordisk A/S by 17.7% in the first quarter. Renaissance Technologies LLC now owns 16,409,200 shares of the company’s stock valued at $562,507,000 after buying an additional 2,463,300 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 12.9% in the second quarter. Fisher Asset Management LLC now owns 11,690,997 shares of the company’s stock valued at $501,427,000 after buying an additional 1,331,992 shares during the last quarter. Karp Capital Management Corp purchased a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $20,651,000. Finally, Sustainable Growth Advisers LP boosted its stake in shares of Novo Nordisk A/S by 17.3% in the first quarter. Sustainable Growth Advisers LP now owns 4,068,896 shares of the company’s stock valued at $139,482,000 after buying an additional 598,644 shares during the last quarter. 6.40% of the stock is owned by institutional investors and hedge funds.
Shares of Novo Nordisk A/S (NYSE:NVO) traded up 3.76% during midday trading on Friday, reaching $45.81. The company’s stock had a trading volume of 2,503,210 shares. The firm has a market cap of $113.62 billion, a price-to-earnings ratio of 18.74 and a beta of 0.63. The company has a 50-day moving average price of $42.76 and a 200-day moving average price of $38.81. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $47.98.
The business also recently declared an annual dividend, which will be paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st will be given a dividend of $0.336 per share. This is a positive change from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date of this dividend is Friday, August 18th. This represents a dividend yield of 1.07%. Novo Nordisk A/S’s payout ratio is 36.00%.
NVO has been the subject of several recent research reports. Zacks Investment Research cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. TheStreet raised Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Finally, BidaskClub cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the stock. Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $53.00.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.